Curis Inc Dossier
Qualitative Analysis
Business overview
Curis, Inc. (NASDAQ: CRIS) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of targeted small molecule drug candidates for the treatment of human cancers. The company's primary strategic focus is emavusertib (CA-4948), an orally available, first-in-class small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4) and FMS-like tyrosine kinase 3 (FLT3). Curis is evaluating emavusertib in combination therapies for hematologic malignancies, including relapsed/refractory primary central nervous system lymphoma (PCNSL) and chronic lymphocytic leukemia (CLL). Following the sale of its Erivedge royalty stream in late 2025, Curis has transitioned into a pure-play clinical-stage entity with no active commercial revenues.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Prioritizing the clinical development of lead candidate emavusertib (CA-4948) in combination therapies, specifically targeting relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with ibrutinib, and chronic lymphocytic leukemia (CLL) in combination with zanubrutinib.
Expected impact: Aims to generate single-arm objective response rate (ORR) data sufficient to support accelerated approval filings with the FDA and conditional marketing authorization with the EMA.
Execution of a private placement (PIPE) financing in January 2026 to secure up to $80.8 million in gross proceeds through the sale of Series B convertible preferred stock and Series A, B, and C warrants.
Expected impact: Provides immediate liquidity and structured milestone-based capital injections (such as the $20.2 million Series B warrant exercise) to extend the operational runway into the second half of 2027.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides Curis with exclusive global licenses (excluding India and Russia) to develop, manufacture, and commercialize emavusertib (CA-4948) and other small molecule candidates targeting immune checkpoints.
Terms: Curis is responsible for clinical development and commercialization, while Aurigene is primarily responsible for preclinical activities and early-stage drug supply.
In November 2025, Curis sold its remaining interest in Curis Royalty LLC (including Erivedge intellectual property and the Genentech license agreement) to Oberland Capital.
Terms: Curis received $2.5 million in upfront cash consideration and achieved the complete release and extinguishment of its liability related to the sale of future royalties to Oberland, resulting in a $27.2 million non-cash gain in Q4 2025.